Codex DNA, Inc. (NASDAQ:DNAY) Short Interest Update

Codex DNA, Inc. (NASDAQ:DNAYGet Rating) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 1,020,000 shares, a growth of 23.0% from the May 15th total of 829,200 shares. Approximately 11.7% of the shares of the stock are sold short. Based on an average trading volume of 286,800 shares, the days-to-cover ratio is presently 3.6 days.

DNAY has been the topic of several recent research reports. Cowen initiated coverage on Codex DNA in a report on Wednesday, March 2nd. They set a “buy” rating on the stock. KeyCorp decreased their price target on Codex DNA from $30.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, March 28th.

NASDAQ:DNAY opened at $2.43 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.33 and a current ratio of 5.48. The stock’s fifty day moving average is $3.97 and its 200 day moving average is $6.60. Codex DNA has a fifty-two week low of $2.32 and a fifty-two week high of $25.70.

Codex DNA (NASDAQ:DNAYGet Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. Codex DNA had a negative return on equity of 46.56% and a negative net margin of 311.52%. As a group, equities analysts predict that Codex DNA will post -2.03 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. increased its stake in Codex DNA by 221.0% in the fourth quarter. Citigroup Inc. now owns 2,838 shares of the company’s stock worth $31,000 after purchasing an additional 1,954 shares during the period. JPMorgan Chase & Co. grew its position in shares of Codex DNA by 87.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,554 shares of the company’s stock worth $60,000 after buying an additional 2,584 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Codex DNA by 1,245.5% during the 4th quarter. Wells Fargo & Company MN now owns 3,606 shares of the company’s stock worth $39,000 after buying an additional 3,338 shares in the last quarter. California State Teachers Retirement System bought a new position in shares of Codex DNA during the 3rd quarter worth $47,000. Finally, American International Group Inc. bought a new position in shares of Codex DNA during the 3rd quarter worth $47,000. Institutional investors and hedge funds own 87.58% of the company’s stock.

About Codex DNA (Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.